BRPI0912656A2 - formulação farmacêutica sólida - Google Patents

formulação farmacêutica sólida

Info

Publication number
BRPI0912656A2
BRPI0912656A2 BRPI0912656A BRPI0912656A BRPI0912656A2 BR PI0912656 A2 BRPI0912656 A2 BR PI0912656A2 BR PI0912656 A BRPI0912656 A BR PI0912656A BR PI0912656 A BRPI0912656 A BR PI0912656A BR PI0912656 A2 BRPI0912656 A2 BR PI0912656A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
solid pharmaceutical
solid
formulation
pharmaceutical
Prior art date
Application number
BRPI0912656A
Other languages
English (en)
Inventor
Tadashi Mukai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40847022&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912656(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0912656A2 publication Critical patent/BRPI0912656A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
BRPI0912656A 2008-05-15 2009-05-14 formulação farmacêutica sólida BRPI0912656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008128259 2008-05-15
PCT/JP2009/059300 WO2009139504A2 (en) 2008-05-15 2009-05-14 A solid pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BRPI0912656A2 true BRPI0912656A2 (pt) 2016-01-26

Family

ID=40847022

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912656A BRPI0912656A2 (pt) 2008-05-15 2009-05-14 formulação farmacêutica sólida

Country Status (32)

Country Link
US (1) US20110091535A1 (pt)
EP (1) EP2273981B1 (pt)
JP (1) JP5552434B2 (pt)
KR (1) KR101585280B1 (pt)
CN (2) CN102119024A (pt)
AR (1) AR071706A1 (pt)
AU (1) AU2009247156B2 (pt)
BR (1) BRPI0912656A2 (pt)
CA (1) CA2722244C (pt)
CL (1) CL2009001183A1 (pt)
CO (1) CO6321223A2 (pt)
CY (1) CY1115955T1 (pt)
DK (1) DK2273981T3 (pt)
EA (1) EA022712B1 (pt)
EC (1) ECSP10010683A (pt)
ES (1) ES2524261T3 (pt)
HK (1) HK1149497A1 (pt)
HR (1) HRP20141134T1 (pt)
IL (1) IL208788A (pt)
MX (1) MX2010012432A (pt)
MY (1) MY153109A (pt)
NZ (1) NZ588794A (pt)
PE (2) PE20140962A1 (pt)
PL (1) PL2273981T3 (pt)
PT (1) PT2273981E (pt)
RS (1) RS53775B1 (pt)
SG (1) SG190643A1 (pt)
SI (1) SI2273981T1 (pt)
TW (1) TWI501789B (pt)
UA (1) UA102547C2 (pt)
WO (1) WO2009139504A2 (pt)
ZA (1) ZA201008115B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
CN103920156B (zh) * 2014-04-04 2016-06-01 成都科特包衣技术有限公司 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法
CN106511313B (zh) * 2016-10-21 2019-06-07 浙江为康制药有限公司 西洛他唑缓释胶囊组合物及其制备方法
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US7138143B1 (en) * 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
MXPA05004422A (es) * 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
JP5112619B2 (ja) * 2004-05-20 2013-01-09 大塚製薬株式会社 固形医薬製剤
WO2007072495A2 (en) * 2005-11-03 2007-06-28 Sun Pharmaceutical Industries Limited Coated tablets having prolonged gastric retention
WO2007105229A1 (en) * 2006-03-14 2007-09-20 Panacea Biotec Ltd. Controlled release pharmaceutical composition and process thereof
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR100963389B1 (ko) * 2006-10-30 2010-06-14 한올바이오파마주식회사 시간차로 방출되는 치아자이드계 화합물과 안지오텐신―ⅱ―수용체 차단제를 포함하는 약학적 조성물
ES2406939T3 (es) * 2007-10-19 2013-06-10 Otsuka Pharmaceutical Co., Ltd. Preparación farmacéutica de matriz sólida
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol

Also Published As

Publication number Publication date
DK2273981T3 (en) 2014-11-24
EA201071309A1 (ru) 2011-06-30
IL208788A0 (en) 2010-12-30
SI2273981T1 (sl) 2015-01-30
WO2009139504A3 (en) 2010-09-30
MY153109A (en) 2014-12-31
ES2524261T3 (es) 2014-12-04
MX2010012432A (es) 2010-12-06
CY1115955T1 (el) 2017-01-25
AR071706A1 (es) 2010-07-07
JP5552434B2 (ja) 2014-07-16
RS53775B1 (en) 2015-06-30
WO2009139504A2 (en) 2009-11-19
PL2273981T3 (pl) 2015-04-30
CA2722244C (en) 2016-09-13
TW201000152A (en) 2010-01-01
HRP20141134T1 (hr) 2015-01-30
CA2722244A1 (en) 2009-11-19
KR20110007255A (ko) 2011-01-21
CO6321223A2 (es) 2011-09-20
CL2009001183A1 (es) 2010-06-18
CN102119024A (zh) 2011-07-06
SG190643A1 (en) 2013-06-28
PE20140962A1 (es) 2014-08-15
NZ588794A (en) 2012-07-27
EP2273981B1 (en) 2014-11-05
ECSP10010683A (es) 2011-01-31
UA102547C2 (uk) 2013-07-25
AU2009247156A1 (en) 2009-11-19
TWI501789B (zh) 2015-10-01
AU2009247156B2 (en) 2013-10-24
PT2273981E (pt) 2015-01-02
ZA201008115B (en) 2012-01-25
EA022712B1 (ru) 2016-02-29
IL208788A (en) 2016-05-31
KR101585280B1 (ko) 2016-01-13
HK1149497A1 (en) 2011-10-07
JP2011520774A (ja) 2011-07-21
EP2273981A2 (en) 2011-01-19
PE20091900A1 (es) 2009-12-31
CN104971037A (zh) 2015-10-14
US20110091535A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
LTPA2018005I1 (lt) Farmacinė kompozicija
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0920521A2 (pt) combinação farmacêutica
SMT201400069B (it) Formulazione farmaceutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0721651A2 (pt) Composição farmacêutica
DK3097925T3 (da) Farmaceutisk sammensætning
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI1004940A2 (pt) composição farmacêutica
RU2493831C3 (ru) Фармацевтические композиции
BRPI0921654A2 (pt) formulação farmacêutica
BRPI1015939A2 (pt) composição farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica
BR112012003149A2 (pt) composição farmacêutica
BRPI0912656A2 (pt) formulação farmacêutica sólida
DK2271321T3 (da) Farmaceutisk sammensætning 271
FI20080348A0 (fi) Uudenlainen farmaseuttinen formulaatio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]